Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.

Researchers have developed a new suite of genetic tools for cell-type specific targeting to battle brain disease.

Research teams have created a versatile set of gene delivery systems that can reach different neural cell types in the human ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

In southeastern Brazil, the world’s most genetically elite cows strut their stuff in bovine beauty pageants. These “supercows ...

Halo Labs believes that by combining with Waters, its ability to expand its platform's reach will enhance drug development ...

A “genetic surgery” or “interventional genetics” system for individualized treatments would be a marriage of drug development ...